Home / Health / Facing trust deficit, Russian, Chinese vaccine could use a shot in the arm

Facing trust deficit, Russian, Chinese vaccine could use a shot in the arm

For an indication of the trust deficit, look at the way the market responded to Russia's green light for its Sputnik V vaccine, or to news the flagship vaccine is more than 90% effective

Coronavirus, vaccine, covid, drugs, clinical trials

Premium

China faced a higher trust hurdle from the start. It saw the first cases and there were questions from the earliest days of the outbreak.

Clara Ferreira Marques | Bloomberg

5 min read Last Updated : Dec 14 2020 | 8:07 AM IST

In a pandemic, trust is everything.

Beijing and Moscow saw early the potential benefits of pulling ahead in the race to produce an effective inoculation against Covid-19. Apart from the public health benefits and the keen awareness in both governments of the need to be self-reliant, a clear win would validate top-down models of government and innovation. It would also mean a much-needed image boost, at home and abroad.

In the end, both have had success. Moscow in August, to great fanfare, became the first to grant regulatory approval for a vaccine, one of its two leading candidates. By then, Beijing had

Topics : Coronavirus Coronavirus Vaccine Coronavirus Tests Pfizer

What you get on BS Premium?

Unlock 30+ premium stories daily hand-picked by our editors, across devices on browser and app.
Pick your 5 favourite companies, get a daily email with all news updates on them.
Full access to our intuitive epaper - clip, save, share articles from any device; newspaper archives from 2006.
Preferential invites to Business Standard events.
Curated newsletters on markets, personal finance, policy & politics, start-ups, technology, and more.

VIEW ALL FAQs

Need More Information - write to us at assist@bsmail.in